EB 003 - Enveric Biosciences
Alternative Names: EB-003 - Enveric BiosciencesLatest Information Update: 18 Sep 2025
At a glance
- Originator Enveric Biosciences
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 2A receptor partial agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Depressive disorders
Most Recent Events
- 16 Sep 2025 Enveric Biosciences receives written response from the US FDA to its request for a pre-IND Type B meeting for EB 003
- 02 Sep 2025 Enveric Biosciences plans a phase-I clinical trial for Depressive disorders and Anxiety disorders in 2026
- 28 Aug 2025 Pharmacodynamics data from preclinical studies in Neuropsychiatric disorders released by Enveric Biosciences